Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/tumor-lysis-syndrome-following-docetaxel-therapy-for-extensive-FrlKVreMsm
References (4)
-
G. Gravis, F. Bladou, N. Salem, G. Macquart‐Moulin, G. Serment, J. Camerlo, D. Genre, V. Bardou, D. Maraninchi, P. Viens (2003)
Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinomaCancer, 98
-
L. Baeksgaard, J. Sørensen (2003)
Acute tumor lysis syndrome in solid tumors—a case report and review of the literatureCancer Chemotherapy and Pharmacology, 51
-
P. Drakos, J. Bar-ziv, R. Catane (1994)
Tumor lysis syndrome in nonhematologic malignanciesAmerican Journal of Clinical Oncology, 17
-
(2003)
Tumor lysis syndrome– medulloblastoma
- Publisher
- Springer Journals
- Copyright
- Copyright © 2004 by Springer-Verlag
- Subject
- Medicine
- ISSN
- 0344-5704
- eISSN
- 1432-0843
- DOI
- 10.1007/s00280-004-0827-9
- pmid
- 15148627
- Publisher site
- See Article on Publisher Site
Abstract
Tumor Lysis Syndrome (TLS) is characterized by biochemical changes due to rapid tumor lysis of malignant cells, usually after chemotherapy. Typically it is seen in patients with hematologic malignancies sensitive to chemotherapy within days of receiving chemotherapy. Recently Baeksgaard and Sorensen reviewed the small number of cases of TLS after treatment of nonhematologic malignancies reported between 1977 and 2002. After careful review of the literature, I describe what appears to be to the first reported case of TLS associated with chemotherapeutic treatment of metastatic prostate cancer.
Journal
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: Aug 1, 2004